Article: Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease.
2007 Volume 82, Issue 5, Page(s) 575–582
Abstract: Objective: To evaluate and compare the cost-effectiveness of long-acting bronchodilators by estimating incremental costs per quality-adjusted life-year (QALY) gained in patients with moderate to severe chronic obstructive pulmonary disease.: Methods: ...
| Abstract | Objective: To evaluate and compare the cost-effectiveness of long-acting bronchodilators by estimating incremental costs per quality-adjusted life-year (QALY) gained in patients with moderate to severe chronic obstructive pulmonary disease. Methods: This cost-effective analysis was conducted from a third-party payer's perspective. The study was a retrospective pooled analysis, and the effectiveness evidence was derived from a systematic review of literature published from January 1, 1980, to April 14, 2006. Incremental QALYs were estimated by converting the St George's Respiratory Questionnaire scores into EuroQoL-5D scores and using these combined scores as the summary benefit measure. Results: The incremental cost per additional QALY was $26,094 (range, $11,780-$77,214) for tiotropium and $41,000 (range, $23,650-$98,750) for salmeterol compared with placebo. The cost per QALY gained was lower with tiotropium compared with salmeterol or ipratropium based on either the pooled data of available trials or a head-to-head trial. Treatment with tiotropium could save $391 per year while gaining 13 quality-adjusted days compared with ipratropium. Conclusion: Tiotropium appears to be more cost-effective than the alternatives and may be the preferred agent for maintenance therapy in patients with moderate to severe chronic obstructive pulmonary disease. Compared with ipratropium, tiotropium could be cost saving. Because of the wide ranges of cost-effectiveness ratios for tiotropium and salmeterol and the significant overlap between them, a large prospective head-to-head trial would help address the uncertainty and confirm the results of this analysis. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Aged ; Albuterol/analogs & derivatives ; Albuterol/economics ; Albuterol/therapeutic use ; Bronchodilator Agents/economics ; Bronchodilator Agents/therapeutic use ; Cost Savings ; Cost-Benefit Analysis ; Female ; Hospitalization/economics ; Humans ; Ipratropium/economics ; Ipratropium/therapeutic use ; Male ; Middle Aged ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/economics ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic ; Salmeterol Xinafoate ; Scopolamine Derivatives/economics ; Scopolamine Derivatives/therapeutic use ; Tiotropium Bromide | |||||
| Chemical Substances | Bronchodilator Agents ; Scopolamine Derivatives ; Salmeterol Xinafoate (6EW8Q962A5) ; Ipratropium (GR88G0I6UL) ; Albuterol (QF8SVZ843E) ; Tiotropium Bromide (XX112XZP0J) | |||||
| Language | English | |||||
| Publishing date | 2007-05 | |||||
| Publishing country | England | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 124027-4 | |||||
| ISSN | 1942-5546 ; 0025-6196 | |||||
| ISSN (online) | 1942-5546 | |||||
| ISSN | 0025-6196 | |||||
| DOI | 10.4065/82.5.575 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ua VI Zs.183: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.